Comparative study of barnidipine and felodipine in chinese patients with essential hypertension

被引:4
作者
Zhu, W. [1 ]
Li, T.
Ni, C.
Liu, H.
Fang, L.
Shang, M.
Kikkawa, T.
Katoh, H.
Yamamoto, M.
机构
[1] Peking Union Med Coll Hosp, Dept Internal Med, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[4] Astellas Pharma Co Ltd, Asian Business Management, Tokyo, Japan
关键词
barnidipine; felodipine; calcium-channel blocker; essential hypertension; Chinese;
D O I
10.1177/147323000603400410
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This study evaluated the efficacy and safety of barnidipine for the treatment of mild-to-moderate essential hypertension in Chinese patients. A total of 131 patients were randomized to receive either barnidipine (10-15 mg) or felodipine (5-10 mg) once daily for 4 weeks. Both drugs reduced blood pressure significantly, with >= 87% of patients obtaining a marked or moderate effect. The mean +/- SD reductions in systolic and diastolic blood pressure were 19.2 +/- 13.6 and 14.4 +/- 7.0 mmHg, respectively, for barnidipine treatment, and 20.3 +/- 11.3 and 14.7 +/- 7.7 mmHg, respectively, for felodipine treatment. There were no significant differences between the two drugs in terms of anti-hypertensive effect, heart rate, laboratory test results or incidence of adverse events. More patients taking felodipine experienced palpitations, but this difference was not statistically significant. Barnidipine is as efficacious and safe as felodipine in the treatment of essential hypertension in Chinese patients.
引用
收藏
页码:406 / 412
页数:7
相关论文
共 27 条
[1]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[2]  
Argenziano L, 1998, Blood Press Suppl, V1, P9
[3]   An open-label, uncontrolled, 8-week clinical trial of barnidipine hydrochloride, a once-daily calcium channel blocker, in Korean patients with essential hypertension [J].
Bae, JH ;
Lee, JJ ;
Kwon, SH ;
Kang, HS ;
Choue, CW ;
Kim, KS ;
Kim, MS ;
Song, JS ;
Yamamoto, M .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (06) :382-389
[4]   PREVALENCE OF HYPERTENSION IN THE US ADULT-POPULATION - RESULTS FROM THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-1991 [J].
BURT, VL ;
WHELTON, P ;
ROCCELLA, EJ ;
BROWN, C ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D .
HYPERTENSION, 1995, 25 (03) :305-313
[5]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[6]   An open-label, randomized, controlled, 4-week comparative clinical trial of barnidipine hydrochloride, a calcium-channel blocker, and benazepril, an angiotensin-converting enzyme inhibitor, in Chinese patients with renal parenchymal hypertension [J].
Chen, X. ;
Zheng, F. ;
Chen, P. ;
Tang, L. ;
Wei, R. ;
Yu, Y. ;
Su, Y. ;
Kikkawa, T. ;
Yamamoto, M. .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2006, 34 (02) :121-128
[7]   THE EFFECT OF PRESCRIBED DAILY DOSE FREQUENCY ON PATIENT MEDICATION COMPLIANCE [J].
EISEN, SA ;
MILLER, DK ;
WOODWARD, RS ;
SPITZNAGEL, E ;
PRZYBECK, TR .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (09) :1881-1884
[8]  
HASHIMOTO K, 1990, KISO TO RINSHO, V24, P4443
[9]  
HORIUCHI I, 1990, SHINRYO TO SHINYAKU, V27, P1135
[10]   Evaluation of the antihypertensive effect barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24 h, daytime, and nighttime [J].
Imai, Y ;
Abe, K ;
Nishiyama, A ;
Sekino, M ;
Yoshinaga, K .
AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) :1415-1419